Cipla Hunts For Biotech Partner In China; Calls Off Deal With India's Avesthagen
MUMBAI - An inordinate delay in the development of three to four biopharmaceuticals by Bangalore-based Avesthagen has led Cipla - India's biggest company in the domestic market - to call off a five-year old partnership and look for joint ventures or collaborations with potential Chinese companies. The disclosure was made to shareholders by Cipla Chairman Yusuf Hamied, at the much-awaited annual general meeting of the company
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
More from Scrip
Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An ‘historic economic prosperity deal’ does not include the sector.